Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH1BVG)

• Drug Name: NCL-1 Drug Info
• Synonyms: NCL-1; GTPL7024; ZINC94568752

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 73755256
  TTD Drug ID: DMH1BVG

Molecule-Related Drug Atlas

Drug(s) Targeting Lysine-specific histone demethylase 1 (LSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IMG-7289	DML9AVG	Acute myeloid leukaemia	2A60	Phase 2	[3]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[3]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[4]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[5]
ORY-2001	DMYM0UY	Alzheimer disease	8A20	Phase 2	[6]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[7]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[8]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[9]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysine-specific histone demethylase 1 (LSD)	TTNR0UQ	KDM1A_HUMAN	Inhibitor	[2]

References

• [1] Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009 Mar 1;69(5):2065-71.
• [2] Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem. 2011 Jun 15;19(12):3702-8.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
• [5] Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
• [6] Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
• [7] A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
• [8] Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
• [9] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [10] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.